Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
The effect of isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF 178; procetofene; Lipanthyl), a new hypolipidemic agent, has been evaluated in 191 patients affected by endogenous hyperlipoproteinemia (IIa, IIb and IV). Data were collected from patients on active drug trial from 1 to 18 months. The daily administered dose varied from 200 to 400 mg according to pretreatment dietary stabilized lipid values. Under the controlled experimental conditions described, LF-178 lowered cholesterol by 20 to 36% in types IIa and IIb and triglycerides by 30 to 50% in types IIa and IV of H. L. P. A comparative trial of LF 178 and clofibrate indicates that the drug is significantly more potent than the reference compound after 1 month of treatment. Tolerance has always been excellent throughout the study.
D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011422:Propionates; D014280:Triglycerides; D002994:Clofibrate